Propentofylline for dementia.

@article{Frampton2003PropentofyllineFD,
  title={Propentofylline for dementia.},
  author={M. Frampton and R. Harvey and V. Kirchner},
  journal={The Cochrane database of systematic reviews},
  year={2003},
  volume={2},
  pages={
          CD002853
        }
}
BACKGROUND Propentofylline is a novel therapeutic agent for dementia that readily crosses the blood-brain barrier and acts by blocking the uptake of adenosine and inhibiting the enzyme phosphodiesterase. In vitro and in vivo its mechanism of action appears to be twofold; it inhibits the production of free radicals and reduces the activation of microglial cells. It therefore interacts with the inflammatory processes that are thought to contribute to dementia, and given its mechanism of action is… Expand
Efficacy and Tolerability of Donepezil in Vascular Dementia
Background and Purpose—Clinical observations suggest that patients with vascular dementia (VaD) may benefit from treatment with cholinesterase inhibitors. This study evaluated the efficacy and safetyExpand
Pharmacological Treatment of Alzheimer’s Disease: Is it Progressing Adequately?
  • A. Robles
  • Medicine
  • The open neurology journal
  • 2009
TLDR
There are multiple molecules used in research to modify AD progression, and it turns out to be difficult to obtain drugs with sufficient efficacy so that their marketing is approved, which would lead to a reduction of AD prevalence. Expand
Chronic Administration of the Methylxanthine Propentofylline Impairs Reinstatement to Cocaine by a GLT-1-Dependent Mechanism
TLDR
Findings indicate that modulating glial physiology with atypical xanthine derivatives like PPF is a potential avenue for developing new medications for cocaine abuse, and support the hypothesis that neuron–glial interactions contribute to mechanisms of psychostimulant addiction, particularly via expression and function of astroglial glutamate transporters. Expand
Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576
TLDR
The results demonstrate that PPF can exert multiple protective effects on both amyloidogenesis and tau hyperphosphorylation in an animal model of AD and indicate that further testing of PPF as a potential therapy in AD is warranted. Expand
Acupuncture for vascular dementia.
TLDR
A comparison of electroacupuncture and acupuncture therapy alone suggested that the former was more effective in promoting the recovery of cognitive function, while the effectiveness of acupuncture for vascular dementia is uncertain. Expand
Efficacy and Tolerability of Donepezil in Vascular Dementia: Positive Results of a 24-Week, Multicenter, International, Randomized, Placebo-Controlled Clinical Trial
TLDR
These data demonstrate that donepezil is an effective and well-tolerated treatment for VaD and show it may have an important place in the management of this condition. Expand
Adenosine hypothesis in schizophrenia and bipolar disorder: A systematic review and meta-analysis of randomized controlled trial of adjuvant purinergic modulators
TLDR
It is suggested that adenosine modulator adjuvant therapy is more beneficial in overall psychopathology (especially positive symptoms) in schizophrenia and in treating mania episodes of BD in comparison to placebo. Expand
Vascular Cognitive Impairment: Disease Mechanisms and Therapeutic Implications
TLDR
Clinical and effectiveness studies with long-term follow-up are needed to determine the benefits and risks of pharmacologic and nonpharmacologic therapies to prevent and treat VCI. Expand
Antiallodynic effects of propentofylline Elicited by interrupting spinal glial function in a rat model of bone cancer pain
TLDR
The results suggest that the glial modulating agent PPF has antiallodynic effects on bone cancer pain and has potential utility for clinical treatment of cancer pain. Expand
FDG PET in dementia multicenter studies and clinical trials
TLDR
Evidence from clinical trials and from observational longitudinal studies demonstrates that regional metabolic decline is closely linked to clinical progression, supporting the use of FDG PET in the assessment of disease-modifying interventions. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 20 REFERENCES
Propentofylline in the Treatment of Alzheimer’s Disease and Vascular Dementia: A Review of Phase III Trials
TLDR
Results from a drug withdrawal study suggested that propentofylline does not merely relieve dementia symptoms but slows the progression of the disease itself, and was found to provide consistent improvements over placebo in efficacy assessments for both AD and VaD patients. Expand
Clinical Trials in Dementia with Propentofylline a
TLDR
Propentofylline showed statistically significant, clinically relevant improvements over placebo in efficacy assessments, both in Patients with Alzheimer's disease and in patients with vascular dementia, and was also well tolerated. Expand
Clinical trials of propentofylline in vascular dementia
TLDR
Beneficial effects of propentofylline were consistently demonstrated in the domains of cognitive and global function for both VaD populations; however, no treatment benefits could be demonstrated for activities of daily living. Expand
Placebo-controlled trial of the xanthine derivative propentofylline in dementia.
TLDR
The results indicate that patient performance can already be enhanced if subjects are required to engage in cognitive tasks and the clinical parameters can be positively influenced by propentofylline. Expand
Investigating the Natural Course and Treatment of Vascular Dementia and Alzheimer's Disease: Parallel Study Populations in Two Randomized, Placebo‐Controlled Trials
Propentofylline is a glial cell modulator that has been shown to interfere with neuroinflammatory processes linked to the pathologic activation of microglial cells and reactive astrocytes — commonExpand
Propentofylline improves regional cerebral glucose metabolism and neuropsychologic performance in vascular dementia
In a double-blind, placebo-controlled trial in thirty patients with mild to moderate vascular dementia (VD) according to DSM-III-R criteria, the effects of the adenosine uptake blockerExpand
Propentofylline in adult-onset cognitive disorders: double-blind, placebo-controlled, clinical, psychometric and brain mapping studies.
TLDR
Electro EEG brain mapping seems to be more sensitive in objectivating central drug effects of propentofylline in elderly outpatients with mild to moderate chronic cognitive disturbances (mild dementia, DSM-III-R). Expand
Propentofylline Treatment for Alzheimer Disease and Vascular Dementia: An Economic Evaluation Based on Functional Abilities
TLDR
Results indicated that propentofylline improved health outcomes of persons with dementia as statistically significant treatment effects were found, and although an incremental cost for the propent ofylline intervention was incurred from the Ministry of Health perspective, home care and, to a larger extent, caregiver costs were reduced. Expand
A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group.
TLDR
In a multinational, randomized, 12-month, double-blind, parallel-group study 260 out-patients with mild to moderate AD or VaD received 300 mg propentofylline or placebo three times daily 1 h before meals to favour its use in both subtypes of dementia. Expand
Propentofylline enhances cerebral metabolic response to auditory memory stimulation in Alzheimer's disease
TLDR
A protective role for propentofylline in slowing the progression of AD is suggested and the drug was well tolerated and showed a significant increase of cerebral metabolic response to the memory task. Expand
...
1
2
...